On October 13, ASYMCHEM fell 3.07% in regular trading, trading at HK$150.3 with turnover of HK$3.3765 million. The decline extended pressure from continued institutional selling of H-shares ahead of the third-quarter results.

Recent disclosures show multiple institutions cut stakes in the company. Executive director Hong Liang sold 59,600 shares on September 15. JPMorgan and Schroders PLC also reduced holdings during late September, with Schroders trimming to 9.65% on September 24. The concentrated institutional repositioning, combined with post-holiday risk aversion, is dominating sentiment in the near term.

Fundamentals remain resilient: order backlog reached US$1.673 billion, up 53.77% year over year, and the large-molecule chemistry site passed a US FDA pre-approval inspection. However, the short-term selling pressure from foreign institutions is currently outweighing these positives.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)